Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H22N2O.2ClH |
| Molecular Weight | 367.313 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C3=C4C=CC=CC4=NC=C3
InChI
InChIKey=ZDBQDNUZNQOCTH-WESSAKMQSA-N
InChI=1S/C19H22N2O.2ClH/c1-2-13-12-21-10-8-14(13)11-18(21)19(22)16-7-9-20-17-6-4-3-5-15(16)17;;/h2-7,9,13-14,18-19,22H,1,8,10-12H2;2*1H/t13-,14-,18-,19+;;/m0../s1
| Molecular Formula | C19H22N2O |
| Molecular Weight | 294.3908 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including
http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500012185.pdf
https://www.ncbi.nlm.nih.gov/pubmed/9776305
Curator's Comment: Description was created based on several sources, including
http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500012185.pdf
https://www.ncbi.nlm.nih.gov/pubmed/9776305
Cinchonidine is an alkaloid found in Cinchona officinalis and Gongronema latifolium. Cinchonidine is an antimalarial drug which has been used clinically in malaria caused by Plasmodium falciparum. Cinchonidine is reported as an ingredient of Quinimax in a number of countries. Quinimax is a combination of four alkaloids (quinine, quinidine, cinchoine and cinchonidine).
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Screening for new compounds with antiherpes activity. | 1984 Oct |
|
| HPTLC method for the estimation of alkaloids of Cinchona officinalis stem bark and its marketed formulations. | 2001 Apr |
|
| In vitro effect of alkaloids on bloodstream forms of Trypanosoma brucei and T. congolense. | 2001 Oct |
|
| Highly selective hydroformylation of the cinchona alkaloids. | 2002 Jul 12 |
|
| Highly stereoselective, uniformly sized molecularly imprinted polymers for cinchona alkaloids in hydro-organic mobile phases. | 2003 Jan |
|
| Direct STM investigation of cinchona alkaloid adsorption on Cu(III). | 2004 Apr 13 |
|
| Short columns with molecularly imprinted monolithic stationary phases for rapid separation of diastereomers and enantiomers. | 2004 May 5 |
|
| Signaling molecularly imprinted polymers: molecular recognition-based sensing materials. | 2005 |
|
| Screening of bitterness-suppressing agents for quinine: the use of molecularly imprinted polymers. | 2005 Feb |
|
| Effect of protonation on the conformation of cinchonidine. | 2006 Dec 13 |
|
| Competitive chemisorption between pairs of cinchona alkaloids and related compounds from solution onto platinum surfaces. | 2006 Dec 27 |
|
| Michael reactions carried out using a bench-top flow system. | 2006 Feb 7 |
|
| Effect of ultrasound in enantioselective hydrogenation of 1-phenyl-1,2-propanedione: comparison of catalyst activation, solvents and supports. | 2006 Jan |
|
| Liquid chromatographic analysis of cinchona alkaloids in beverages. | 2006 Jul-Aug |
|
| Improved asymmetric S(N)Ar reaction of beta-dicarbonyl compounds catalyzed by quaternary ammonium salts derived from cinchona alkaloids. | 2006 Jun 23 |
|
| Determination of geometric orientation of adsorbed cinchonidine on Pt and Fe and quiphos on Pt nanoclusters via DRIFTS. | 2006 Mar 21 |
|
| The origin of chemo- and enantioselectivity in the hydrogenation of diketones on platinum. | 2006 Mar 29 |
|
| Enantioselective hydrogenation of ethyl pyruvate over diop modified Pt nanoclusters. Determination of geometry of the ligand adsorption mode via DRIFTS. | 2007 Feb 21 |
|
| Diastereo- and enantioselective synthesis of alpha,beta-epoxyketones using aqueous NaOCl in conjunction with dihydrocinchonidine derived phase-transfer catalysis at room temperature. Scope and limitations. | 2007 Jul 21 |
|
| Pilot feasibility study of an emergency paediatric kit for intra-rectal quinine administration used by the personnel of community-based health care units in Senegal. | 2007 Nov 15 |
|
| Phthalocyanine-based molecularly imprinted polymers as nucleoside receptors. | 2008 |
|
| Conformational behavior of cinchonidine revisited: a combined theoretical and experimental study. | 2008 Aug 7 |
|
| Influence of peripheral groups on the physical and chemical behavior of cinchona alkaloids. | 2009 Aug 27 |
|
| Preparative resolution of etodolac enantiomers by preferential crystallization method. | 2009 Oct |
|
| Shape-selective enantioselective hydrogenation on Pt nanoparticles. | 2009 Sep 2 |
|
| Synthesis and biological activity of the calcium modulator (R) and (S)-3-methyl 5-pentyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate. | 2010 Feb 1 |
|
| Practical asymmetric conjugate alkynylation of Meldrum's acid-derived acceptors: access to chiral beta-alkynyl acids. | 2010 Jan 20 |
|
| Chiral recognition in cinchona alkaloid protonated dimers: mass spectrometry and UV photodissociation studies. | 2010 Mar 11 |
Sample Use Guides
Fifty-five children were given 20 mg/kg of the diluted injectable form of Quinimax (a quinine, quinidine, cinchonine, cinchonidine association) intrarectally. A further 11 children with malaria were treated with 12.5 mg/kg of the same Quinimax solution by the intramuscular route. All the children were treated twice a day for 3 d.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 06:43:31 GMT 2023
by
admin
on
Sat Dec 16 06:43:31 GMT 2023
|
| Record UNII |
QNY56C6XYZ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
524-54-9
Created by
admin on Sat Dec 16 06:43:31 GMT 2023 , Edited by admin on Sat Dec 16 06:43:31 GMT 2023
|
PRIMARY | |||
|
SUB125748
Created by
admin on Sat Dec 16 06:43:31 GMT 2023 , Edited by admin on Sat Dec 16 06:43:31 GMT 2023
|
PRIMARY | |||
|
DTXSID70200414
Created by
admin on Sat Dec 16 06:43:31 GMT 2023 , Edited by admin on Sat Dec 16 06:43:31 GMT 2023
|
PRIMARY | |||
|
45073521
Created by
admin on Sat Dec 16 06:43:31 GMT 2023 , Edited by admin on Sat Dec 16 06:43:31 GMT 2023
|
PRIMARY | |||
|
100000146237
Created by
admin on Sat Dec 16 06:43:31 GMT 2023 , Edited by admin on Sat Dec 16 06:43:31 GMT 2023
|
PRIMARY | |||
|
QNY56C6XYZ
Created by
admin on Sat Dec 16 06:43:31 GMT 2023 , Edited by admin on Sat Dec 16 06:43:31 GMT 2023
|
PRIMARY | |||
|
m3559
Created by
admin on Sat Dec 16 06:43:31 GMT 2023 , Edited by admin on Sat Dec 16 06:43:31 GMT 2023
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |